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Abstract
An encouraging approach for the diagnosis and effective therapy of immunological pathologies, which would
include cancer, is the identification of proteins and phosphorylated proteins. Disease proteomics, in particular, is a
potentially useful method for this purpose. A key role is played by protein phosphorylation in the regulation of
normal immunology disorders and targets for several new cancer drugs and drug candidates are cancer cells and
protein kinases. Protein phosphorylation is a highly dynamic process. The functioning of new drugs is of major
importance as is the selection of those patients who would respond best to a specific treatment regime. In all
major aspects of cellular life signalling networks are key elements which play a major role in inter- and intracellular
communications. They are involved in diverse processes such as cell-cycle progression, cellular metabolism, cell-cell
communication and appropriate response to the cellular environment. A whole range of networks that are
involved in the regulation of cell development, differentiation, proliferation, apoptosis, and immunologic responses
is contained in the latter. It is so necessary to understand and monitor kinase signalling pathways in order to
understand many immunology pathologies. Enrichment of phosphorylated proteins or peptides from tissue or
bodily fluid samples is required. The application of technologies such as immunoproteomic techniques,
phosphoenrichments and mass spectrometry (MS) is crucial for the identification and quantification of protein
phosphorylation sites in order to advance in clinical research. Pharmacodynamic readouts of disease states and
cellular drug responses in tumour samples will be provided as the field develops. We aim to detail the current and
most useful techniques with research examples to isolate and carry out clinical phosphoproteomic studies which
may be helpful for immunology and cancer research. Different phosphopeptide enrichment and quantitative
techniques need to be combined to achieve good phosphopeptide recovery and good up- and-down phospho-
regulation protein studies.
Background
Importance of the field
The personalized management of diseases has and is being
extended and this implies the prescription of specific ther-
apeutics best suited for the individual patient and his/her
type of illness. With the combination of different proteo-
mic strategies this can be improved, and this would imply
the coupling of proteomic and clinical research.
Areas covered in this review
Clinical and Proteomic research can be carried out in a
complementary manner in order to advance and innovate
therapies and diagnostics. We also point out the impor-
tance of immunology diseases including cancer, especially
those which are directly connected to phosphorylated
protein kinases and the way in which to isolate and
methodologically analyse phosphoproteins-phosphopep-
tides, with their advantages and disadvantages, when
using proteomic tools.
What the reader will gain
An overview of various types of different proteomic strat-
egy-combinations personalized for specific diseases. The
principles of phosphoproteomic techniques with examples
are also presented in a simple manner. In addition, impor-
tant mass spectrometry clues will be detailed in order to
identify and correctly assign a phosphate group in a phos-
phorylated protein.
Take home message
A high number of proteomic-combination-approaches are
available for clinical research. It is always necessary to test
different proteomic tools in order to raise a greater level of
efficiency for your clinical proteomic study, especially
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any medium, provided the original work is properly cited.those related to phosphorylated proteins which are poorly
expressed as some kinases. Nowadays it is essential that
clinicians and proteomic experts work together in order to
improve the therapies and drug candidates development.
We aim to detail the current and most useful techni-
ques with research examples to isolate and carry out
clinical phosphoproteomic studies which may be helpful
for immunology and cancer research. Different phos-
phopeptide enrichment and quantitative techniques
need to be combined to achieve good phosphopeptide
recovery and good up- and-down phospho-regulation
protein studies.
(A) Phosphorylation’s role in immune disorders and cancer
Phosphorylation and de-phosphorylation at serine, threo-
nine and tyrosine residues are one of the most common
mechanisms of activation and/or inactivation signalling
pathways. A variety of cellular processes including cellu-
lar growth, proliferation, cell cycle control, cytoskeletal
mobility and receptor regulation [1] are controlled by
this type of modification. Phosphorylation leads to allos-
teric modifications that mayr e s u l ti nc o n f o r m a t i o n a l
changes sufficient to cause activation or inactivation of
various proteins and associated altered functioning. It is
our hypothesis that identification of phosphoproteins
associated with the various stages of different immunolo-
gical disorders, including cancer, may provide informa-
tion on the development of the pathology. In addition
the mechanism of tumorigenesis gives us insight into the
development of diagnostic and therapeutic procedures.
The mitogen activated protein kinase (MAPK) pathways
are known to be deregulated in many human malignancies
[2-5]. With relation to malignancy, the best studies
MAPKs are the extracellular signal regulated protein
kinases (ERK). ERKs phosphorylate cytoplasmic targets
migrate to the nucleus where they can activate transcrip-
tion factors involved in cellular proliferation. Eractic signal-
ling in the MAPK/ERK pathways has been described in
prostate, breast and colon cancers in vitro as well as in vivo
models [6-9]. In cervical cancer, furthermore, a study has
described decreased activation of ERK1/2 in invasive cervi-
cal carcinoma [10]. Annexin A1, which is a calcium depen-
dent phospholipid binding protein that has been linked to
membrane trafficking through exocytosis and endocytosis
[11], is a second relevant example. Other studies have eval-
uated the role of annexin A1 in the modulation of the
MAPK/ERK [12]. In fact, many members of the Annexin
family are known to undergo alternative splicing yielding a
number of isoforms. The resulting variant forms may have
different functions and binding capacity in comparison to
the native forms [13]. The DNA-Protein Kinase catalytic
subunit (DNA-PKcs) - another relevant example - a
macromolecule found to be involved in the repair of dou-
ble stranded DNA fractures through activation of p53,
found to be expressed in cancer specimens in its tyrosine
phosphorylated and cleaved form [14]. In contrast, in nor-
mal specimens DNA-PKcs existed in its whole, full length
in non-phosphorylated form. This study was aimed at iden-
tifying differential expression and modification of proteins
that could suggest erratic pathways which could serve as
novel targets for developing new therapies in the treatment
of cervical cancer and help in monitoring disease recur-
rence or progression. The general principles of signalling
pathways are illustrated (Figure 1) and also, an example of
the structure of a relevant phosphorylated protein kinase
(Figure 2).
On the other hand, the CDC25 family of proteins con-
sists of dual specificity phosphatases which regulate cell
cycle transitions, and they are key targets for the check-
point machinery to maintain genome stability during
DNA damage. Three isoforms of CDC25 have been identi-
fied in mammalian cells: CDC25A, CDC25B, and
CDC25C. CDC25A and CDC25B over-expression has
been reported in many types of human cancers, but these
are insufficient to cause cancer, and the mechanism
responsible for CDC25 over-expression is unclear [15,16].
The study of dose-response effects of the anti-cancer drug
rapamycin on the phosphoproteomics level has identified
hundreds of novel rapamycin-targeted cellular proteins
and their phosphorylation sites. This information has
enabled us to identify CDC25B as the key enzyme in med-
iating rapamycin induced oncogenic AKT activation. It is
important to point out that we can demonstrate that phos-
phoproteomic profiling of a certain therapeutic agent does
not only identify potential drug target(s) to improve the
efficiency of that therapeutic approach in disease treat-
ment, but it can also provide cellular information about
possible beneficial and adverse side effects of a specific dis-
ease therapy when treating patients [17].
In addition, primary immunodeficiencies (PID) are “nat-
ure’s experiments” which have allowed, not only the eluci-
dation of many signalling pathways, but also their function
an clinical relevance. Bruton’s tyrosine kinase, is an inter-
esting example: (Btk; member of the Tec family of kinases)
[18,19], important in B-lymphocyte development, differen-
tiation, and signalling. Btk is predominantly expressed in B
lymphocytes and monocytes but not in plasma cells
[20,21]. Btk expression in the B-cell lineage is also devel-
opmentally regulated, with bone marrow derived hemato-
poietic stem cells, common lymphoid progenitor cells,
developing B and myeloid lineages showing the highest
levels, whereas the remaining mature cells prior to activa-
tion have reduced cellular Btk. What remains to be estab-
lished is the physiological significance of Btk expression in
other cell types as B lymphocytes are the only cells known
to be affected in X-linked agammaglobulinemia (XLA).
Mutations in the Btk gene lead to XLA in humans and
X-linked immunodeficiency (Xid) in mice. Activation of
Btk triggers a cascade of signalling-events that culminates
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cytoskeletal rearrangements, and transcriptional regulation
involving nuclear factor-B (NF-B) and nuclear factor of
activated T cells (NFAT). In B cells, NF-B was shown to
bind to the Btk promoter and induce transcription,
whereas the B-cell receptor dependent NF-B signalling
pathway requires functional Btk. In addition, Btk activa-
tion is strictly regulated by a plethora of other signalling
proteins including protein kinase C (PKC), Sab/SH3BP5,
and caveolin-1. Additionally, the prolyl isomerase Pin1
negatively regulates Btk by decreasing tyrosine phosphory-
lation and uniform state levels of Btk [22]. It is of great
interest that PKC and Pin1, both of which are negative
regulators of Btk, bind to the pleckstrin homology domain
of Btk. For this purpose, novel mutations in the pleckstrin
homology are under research, in order to design selective
Figure 1 Signalling pathways: general principles. Followed by communication of the signal to different cellular compartments are signal
processing and amplification by plasma membrane proximal events. The activation of multiple signal cascades by receptors, different protein
post-translational modifications (PTMs), crosstalk between signalling pathways and feedback loops to ensure optimal signalling output are
involved in this process. The binding of receptor Tyr kinases (RTKs) to their cognate ligands at the cell surface results in receptor dimerization
and autophosphorylation. Phosphorylated Tyr residues subsequently serve as docking sites to recruit signalling mediators, such as growth factor
receptor-bound protein 2 (GRB2). Multiple signalling cascades such as the phosphoinositide-3 kinase (PI3K)-AKT, Ras-Raf- extracellular signal-
regulated kinase (ERK) mitogen-activated protein kinase (MAPK), and signal transducer and activator of transcription (STAT) pathways are
activated by the assembly of these signalling complexes. Casitas B-lineage lymphoma (CBL)-mediated ubiquitylation of RTKs controls their
endocytosis and the duration of receptor signalling. In addition, binding of tumour necrosis factor-a (TNFa) to its receptor, TNFR1, induces
trimerization of the receptor and recruitment of the adaptor protein TNFR1-associated death domain (TRADD) This functions as a hub to
assemble a multiprotein signalling complex containing TNFR-associated factor 2 (TRAF2), receptor interacting Ser/Thr protein kinase 1 (RIPK1) and
nuclear factor-B (NF-B) essential modulator (NEMO). The result is the activation of different signalling networks, such as the ERK MAPK, p38
MAPK and NF-B pathways. Proteins in the MAPK signalling pathways are activated by both RTKs and TNFa, which allows cells to integrate
multiple signals. [Dotted lines indicate indirect activation of signalling pathways or translocation of proteins into the nucleus. IB, inhibitor of
NF-B; IKK, inhibitor of NF-B kinase; JNK1, Jun N-terminal kinase 1; MEK, MAPK ERK kinase; mTOR, mammalian target of rapamycin; p70S6K, p70
ribosomal S6 kinase-a; RSK, ribosomal protein S6 kinase-a].
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(CVID) is a PID disease. CVID is the result of intrinsic
deficits affecting immunologic functions. Moreover lym-
phomas and neoplams are found to be related to CVID.
CVID is heterogeneous, can be present early or late in life,
and it is associated with specific comorbidities [24,25].
Efforts to subcategorize CVID to predict outcomes and
comorbid-condition, both clinically and based on immu-
nologic phenotypes, are ongoing [26]. B cell-activating fac-
tor of the TNF family receptor [27], transmembrane
activator, calcium modulator, cyclophilin ligand interactor
(TACI) [28-30], and certain HLA haplotypes [31,32] have
been identified as potential gene candidates for susceptibil-
ity to CVID. Inducible costimulator [33,34], CD81 [35],
CD19 [36,37] and CD20 [38] harbour disease-causing
mutations that presently explain only a small percentage
of cases [39]. Recently, a genome-wide association work
[40] has identified diverse causes of common variable
immunodeficiency providing new mechanistic insights
into immunopathogenesis based on these unique genetic
variations. A highly significant number of subjects with
duplications in ORC4L, a gene previously associated with
Figure 2 Example of a phosphorylated protein kinase. The location of phosphorylated Ser-279 in the protein structure of human MAP kinase
p38beta (p38B) is shown in this figure. A model for phosphorylated serine was located in the structural position of residue Ser-279 in the 3D
crystallographic coordinates of p38B (Protein Data Bank code: 3GC8). Position of the ATP binding site is indicated. Plot was generated using
PyMOL (DeLano Scientific, San Carlos, CA). The p38 pathway is one of the mitogen-activated protein kinase (MAPK) signalling cascades along
with the extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) pathways. Similar to other MAPK pathways, the p38
signalling cascade involves sequential activation of MAPK kinases (MAP3Ks) and MAPK kinases (MKKs) including MKK3, MKK4, and MKK6, which
directly activate p38 through phosphorylation in a cell-type- and stimulus-dependent manner. Once activated, p38 MAPKs phosphorylate serine/
threonine residues on their substrates, such as transcription factors, cell cycle regulators as well as protein kinases. By the p38 signalling pathway
cells can interpret a wide range of external signals, such as inflammation, hyperosmorality, UV radiation and oxidative stress and they respond
appropriately by generating an excessive abundance of different biological effects.
López et al. Proteome Science 2011, 9:27
http://www.proteomesci.com/content/9/1/27
Page 4 of 20B-cell lymphoproliferative disorders was observed. All
these new insights could be susceptible to phosphoproteo-
mic analysis in order to clarify the clues of the different
pathologies [41].
(B) Analytical techniques used in phosphoproteomics
B.1. Preparation of samples The key to any successful
analysis is good sample preparation; phosphorylated pro-
teins are quite stable, chemically, but there are highly
susceptible to enzymatic modification. We emphasize the
importance of phosphorylation of protein kinases due to
t h ef a c tt h a tt h e ym o d u l a t em a n yi m m u n o l o g yd i s e a s e s
and they are usually poorly expressed. Moreover, the
human genome contains around 500 kinases and over
100 phosphatases [42], so that when tissues or cells are
lysed and extracted, it is highly probable that further
enzymatic reactions will occur. Samples have to be pre-
pared (a) quickly, (b) generally be snap-frozen and (c)
treated with phosphatase inhibitors to avoid modification
of phosphopeptides during sample work-up [43,44].
Phosphopeptides generally constitute a small portion of
the peptides in a given protein sample, making them dif-
ficult to detect by MS; their enrichment helps to over-
come this problem. It is important (d) to avoid salts and
detergents, which can decrease the recovery of phospho-
peptides and/or interfere with subsequent analysis [45].
B.2. Enrichment of phosphoprotein and phosphopeptide
The aim in many focuses, including the study of immune
disorders, is to generate a global view of serine, threonine
and tyrosine phosphorylation within the sample, concen-
trating specifically on the selected subset of phosphopep-
tides. Since the detection of phosphopeptides by MS is
often hindered by suppression effects, many different
strategies have been established: for the removal of
unphosphorylated peptides: (I) immunoprecipitation by
antibodies, (II) pre-fraction systems such as ionic chro-
matographic exchange (SCX/SAX), calcium phosphate
precipitation and hydrophilic interaction chromatography
(HILIC) (III) metal affinity chromatography i.e. IMAC,
TiO2,Z r O 2, and (IV) reverse phase chromatography (RP).
(V) Immunoprecipitation of phosphotyrosine coupled or
not to polyacrylamide gels, is still much more frequent
[43] than immunoprecipitation using phospho- serine or
threonine antibodies. This is because affinity chromato-
graphy such as IMAC or titanium dioxide has higher a
capacity for phosphoserine and phosphothreonine peptide
binding.
￿ Antibody purification and Polyacrylamide gels Affi-
nity purification, a method for purifying proteins, can be
used together with SDS-PAGE or alone. Antibodies raised
against a protein can be used to immunoprecipitate the
protein and search for phosphorylation sites. Immunopre-
cipitation permits the isolation of a protein under a variety
of biological conditions to assess changes in phosphoryla-
tion on that protein. In the same way, antibodies raised
against a specific phosphosite on a protein can be used for
immunoprecipitation. Assessment of other phosphosites
on a protein is possible when one phosphosite is known
(the epitope of the antibody) under this scenario. However,
care must be taken when a protein is phosphorylated at
multiple serines as certain phosphorylation events could
be mutually exclusive and be obliterated during subse-
quent analysis. Phosphospecific antibodies can be used to
determine the proteins that bind to a phosphoprotein
(protein-phosphoprotein interactions) using phosphosite-
specific immunoprecipitation followed by analysis of the
binding partners. Furthermore, antibodies specific for
phosphotyrosines, not affected by the surrounding amino
acids, have been successfully used to immunoprecipitate
the “phosphotyrosineome” of cells. Since phosphoserine
and phosphothreonine are much more abundant in cells
and these antibodies seem to have less specificity, phos-
phoproteome-wide experiments are much more compli-
cated [46].
Moreover, phospho-specific antibodies against a consen-
sus sequence-motif for a specific kinase-motif (for example
SXR, where × is any amino acid) can also be used to
immunopurify all proteins that contain this motif. This
form of phosphorylation has been enriched by the use of
antiphosphotyrosine antibodies. It is an interesting strategy
as phosphotyrosine is far less common than phosphoserine
or threonine; the antibodies generally have a higher specifi-
city and tyrosine kinases play a prominent role in human
cancer. The isolated proteins are enzymatically cleaved
with trypsin and analysed by MS or the phosphopeptides
can be further enriched for analysis by MS. Tyrosine phos-
phorylated proteins are enriched by these methods to levels
sufficient for detection and sequencing by MS [47-52].
Antiphosphoserine and antiphosphothreonine antibodies
have been also generated [43] but have not been widely
used due to their low specificity.
We would like to mention the scientific study of Kemna
and co-workers (2007) [53], who used immunocapture,
and tandem MS to identify and characterize hepcidin in
serum and urine. In addition to diagnostic application,
they investigated analytical reproducibility and biological
and preanalytical variation for both serum and urine sam-
ple fluids. Samples were obtained from healthy controls
and patients with documented iron-deficiency anaemia,
inflammation-induced anaemia, thalassemia major, and
hereditary hemochromatosis. This important proteomic
technique showed that hepcidin-20, -22, and -25 isoforms
are present in urine. Hepcidin-25 in serum had the same
amino acid sequence as hepcidin-25 in urine, whereas
hepcidin-22 was not detected in serum. In this work,
K e m n aa n dc o - w o r k e r s( 2 0 0 7 )a l s oo b s e r v e dt h a tu r i n e
hepcidin is more affected by multiple freeze-thaw cycles
and storage conditions, but less influenced by diurnal var-
iation, than serum hepcidin.
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interesting scientific work where they described the results
of a proteomic analysis based on SDS-PAGE, immunoblot
and mass spectrometry, aimed at the identification of
secreted proteins that are differently expressed at 30°C ver-
sus 37°C and at mid-exponential versus early-stationary
growth phase and antigenic proteins from Rhodococcus
equi ATCC 33701. A total of 48 proteins were identified
irrespective of growth conditions. Cholesterol oxidase
ChoE appears to be the major secretory protein. Four pro-
teins, in addition, revealed high homologies with the myco-
lyl transferases of the Ag85 complex from Mycobacterium
tuberculosis. 24 proteins are transported by a signal pep-
tide-dependent pathway according to the prediction of the
sequence analysis. Moreover, five antigenic proteins of
R. equi were identified by immunoblot, including a novel,
strongly immunoreactive protein of unknown function. In
conclusion, the elucidation of the secretome of R. equi
identified several proteins with different biological func-
tions and a new candidate developing vaccines against
R. equi infection in horses.
Radio-labelling polyacrylamide gels (P32 & 2DE) and 2D
phosphopeptide mapping P32 labelling has long
been used, on the other hand, for the analysis of immuno-
precipitated and gel-separated signalling complexes and
for quantify cation of differentially phosphorylated pro-
teins by two-dimensional gel electrophoresis (2DE) of total
cell lysates. The latter technique uses differential labelling
of cells with P32 and P33 in a control and experimental
group respectively. The samples are combined, and then
separated by 2DE before the gels are exposed twice to
radio-sensitive film. Comparison of these two exposures
will reveal spots that are specifically phosphorylated under
the experimental conditions tested [55,56]. It measures the
incorporation of the label but not the phosphorylation
level, although interesting studies can be carried out
to study different isoforms of the same protein [57].
Two-dimensional (2D) phosphopeptide mapping by elec-
trophoresis is another useful technique combined with
thin-layer chromatography of peptides derived by proteo-
lysis of a phosphoprotein. The number of spots detected
indicates the number of sites of phosphorylation, but it is
not easy to determine the position of the phosphorylation
sites. Nevertheless, analysis of temporal and positional
changes in a protein phosphorylation pattern under differ-
ent physiological conditions [58] is permitted by this tech-
nique. Immunoprecipitation with specific antibodies
against phosphopeptides can be used to immunoprecipi-
tate phosphoproteins from the cell lysates [59].
￿ Immobilised metal ion affinity chromatography
(IMAC) IMAC [60] is an enrichment technique that
makes use of metal ions to capture and enrich negatively
charged phosphopeptides prior to mass spectrometric
analysis [61-66]. Simple and complex samples containing
phosphopeptides and non-phosphorylated peptides are
dissolved in an acidic solution to stimulate the electro-
static interactions between the negatively charged pep-
tides, mainly phosphopeptides, and the metal ions [64].
The phosphopeptides are eluted from the stationary
phase using alkaline buffers. It is also possible to bind
peptides containing the acidic amino acid residues gluta-
mic acid and aspartic acid to the metal ions. Ficarro and
co-workers [67] bypassed this problem with IMAC (Fe
3+)
by converting acidic amino acid residues to methyl esters.
They were able to purify and sequence hundreds of phos-
phopeptides from yeast, although there was a strong ten-
dency towards phosphoproteins highly expressed within
the cell.
Collins and co-workers (2008) [68] analyzed the mouse
forebrain cytosolic phosphoproteome using sequential
(protein and peptide) IMAC purifications, enzymatic
dephosphorylation, and targeted tandem mass spectrome-
try analysis strategies (MS clues will be detailed later)
which we consider a relevant biological study. To sum-
marize, Collins et al., (2008) [68] with the use of comple-
mentary phosphoenrichment and LCMS/MS strategies,
512 phosphorylation sites on 540 nonredundant phospho-
peptides from 162 cytosolic phosphoproteins were charac-
terized. Analysis of protein domains and amino acid
sequence composition of this data set of cytosolic phos-
phoproteins revealed that it is significantly enriched in
intrinsic sequence disorder, which enrichment is asso-
ciated with both cellular location and phosphorylation sta-
tus. The majority of phosphorylation sites found by MS
were located outside structural protein domains (97%)
They were mostly located in regions of intrinsic sequence
disorder (86%). 368 phosphorylation sites were located in
long regions of disorder (over 40 amino acids long), and
94% of proteins contained at least one such long region of
disorder. In addition, it was found that 58 phosphorylation
sites in this data set occur in 14-3-3 binding consensus
motifs; linear motifs that are associated with unstructured
regions in proteins. These results demonstrate that in this
data set protein phosphorylation is distinctively depleted
in protein domains and distinctively enriched in disor-
dered protein sequences and that enrichment of intrinsic
sequence disorder may be a common feature of phospho-
proteomes. This goes to support the hypothesis that disor-
dered regions in proteins allow kinases, phosphatases, and
phosphorylation-dependent binding proteins to gain
access to target sequences to regulate local protein confor-
mation and activity.
￿ Titanium dioxide metal-based chromatography
(TiO2) TiO2 is also capable of binding negatively charged
phosphate groups from aqueous solutions [65,69,70].
TiO2, like IMAC, experiences the problem of binding
acidic non-phosphorylated peptides (negatively charged
peptides). Heck and co-workers [65] observed a number
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recommended esterification of the acidic residues prior to
the MS analysis. Larsen et al. [45,71,41] used 2,5-dihy-
droxybenzoic acid (DHB) with TiO2 and achieved higher
specificity and yield compared to IMAC (Fe
3+)f o rt h e
selective enrichment of phosphorylated peptides from
model proteins. It was also demonstrated that by the use
of glycolic acid in the loading buffer, more phosphopep-
tides are bound to the metal ions and more phosphopep-
tides can be eluted by using ammonium hydroxide as the
eluent. TiO2 binds multi-phosphorylated peptides in a
strong way, thus their elution is difficult. However, this is
a very effective method for the isolation of singly phos-
phorylated peptides [72].
The research work of Craft and co-workers (2007) [73]
is an interesting example of the application of TiO2 tech-
nique coupled to other proteomic tools. Amphiphysin I
(amphI) is dephosphorylated by calcineurin during nerve
terminal depolarization and synaptic vesicle endocytosis
(SVE). Some amphI phosphorylation sites (phosphosites)
have been identified with in vitro studies or phosphopro-
teomics screens. A multifaceted strategy including 32P
tracking to identify all in vivo amphI phosphosites and
determine their relative abundance and potential rele-
vance to SVE was used. AmphI was extracted from 32P-
labeled synaptosomes; phosphopeptides were isolated
from proteolytic digests using TiO2 chromatography, and
mass spectrometry revealed 13 sites: serines 250, 252,
262, 268, 272, 276, 285, 293, 496, 514, 539, and 626 and
Thr-310. These were distributed into two clusters around
the proline-rich domain and the C-terminal Src homol-
ogy 3 domain. Hierarchical phosphorylation of Ser- 262
preceded phosphorylation of Ser-268, -272, -276, and
-285. Off-line HPLC (High-performance liquid chroma-
tography or high-pressure liquid chromatography separa-
tion and two-dimensional tryptic mapping of 32P-labeled
amphI revealed that Thr-310, Ser-293, Ser-285, Ser-272,
Ser-276, and Ser-268 contained the highest 32P incor-
poration and were the most stimulus-sensitive. Individu-
ally Thr-310 and Ser-293 were the most abundant
phosphosites, incorporating 16 and 23% of the 32P. The
multiple phosphopeptides containing Ser-268, Ser-276,
Ser-272, and Ser-285 had 27% of the 32P. Evidence for a
role for at least one proline-directed protein kinase and
one non-proline-directed kinase was obtained. Four
phosphosites predicted for non-prolinedirected kinases,
Ser-626, -250, -252, and -539, contained low amounts of
32P and were not depolarization-responsive. At least one
alternatively spliced amphI isoform was identified in
synaptosomes as being constitutively phosphorylated
b e c a u s ei td i dn o ti n c o r p o r a t e3 2 Pd u r i n gt h e1 - hl a b e l -
ing period. Multiple phosphosites from amphIco- migrat-
ing synaptosomal proteins were also identified, including
SGIP (Src homology 3 domain growth factor receptor-
bound 2 (Grb2)-like (endophilin)-interacting protein 1),
AAK1, eps15R, MAP6, a/b- a d d u c i n ,a n dH C N 1 .T h e i r
results revealed two sets of amphI phosphosites that are
either dynamically turning over or constitutively phos-
phorylated in nerve terminals and they improve the
understanding of the role of individual amphI sites or
phosphosite clusters in synaptic SVE.
￿ IMAC (SIMAC) Sequential elution Sequential elution
from IMAC is useful for purifying, detecting and charac-
terising phosphorylated peptides from complex biological
samples [72]. It makes use of the observation that mono-
phosphorylated peptides tend to elute from IMAC (Fe
3+)
under acidic conditions whereas multi-phosphorylated
peptides elute at high basic pH. TiO2 is used to capture
and purify the unbound mono-phosphorylated peptides
in the combined IMAC flowthrough and washings.
SIMAC has been used successfully in the study of human
stem cells (~300 μg) with more than 300 phosphopep-
tides, including the identification of mono and multiply
phosphorylated peptides [74].
This technology was developed by Tine E. Thingholm
and co-workers (2007) [74]. They reported a simple and
rapid strategy, SIMAC (sequential elution from IMAC),
using stem cells as a sample to be studied, for sequential
separation of monophosphorylated peptides and multiply
phosphorylated peptides from highly complex biological
samples. This research study, allowed individual analysis
of different pools of phosphorylated peptides using mass
spectrometric parameters differentially optimized due to
their unique properties. They compared the phosphopro-
teome identified from 120 μg of human mesenchymal
stem cells using SIMAC and an optimized titanium diox-
ide chromatographic method. More than double the total
number of identified phosphorylation sites was obtained
with SIMAC, primarily from a 3-fold increase in recovery
of multiply phosphorylated peptides.
￿ Zirconium dioxide (ZrO2) The utility of ZrO2 for phos-
phopeptide isolation prior to mass spectrometric analysis
has been demonstrated [75]. When compared with TiO2
using is a and ß casein as protein models, ZrO2 was cap-
able of isolating singly phosphorylated peptides more
selectively than TiO2. An interesting research study was
carried out by Houjiang Zhou et al (2007) [76] where the
high specificity of this approach was also demonstrated
by the isolation of phosphopeptides from the digests of
model phosphoproteins. The strong affinity of ZrO2
nanoparticles to phosphopeptides enables the specific
enrichment of phosphopeptides from a complex peptide
mixture in which the abundance of phosphopeptides is
two orders of magnitude lower than that of nonphospho-
peptides. ZrO2 nanoparticles were further applied to
selectively isolate phosphopeptides from the tryptic diges-
tion of mouse liver lysate for phosphoproteome analysis
by nanoliter LC MS/MS (nano-LC-MS/MS) and MS/MS/
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identified a total of 248 defining phosphorylation sites
and 140 phosphorylated peptides. Therefore, ZrO2 has
been successfully used in the large-scale characterisation
of phosphoproteins from mouse liver samples (~1 mg)
[76]. A total of 248 phosphorylation sites and 140 phos-
phorylated peptides were identified in this study.
￿ Calcium phosphate precipitation This is a strategy
providing a useful pre-fractionation step to simplify and
enrich phosphopeptides from complex samples. Zhang
and co workers [77] have demonstrated that phosphopep-
tide precipitation by calcium phosphate combined with a
two step IMAC (Fe
3+) procedure resulted in the observa-
tion of an increased number of phosphopeptides. This
method consists of precipitating phosphopeptides by add-
ing 0.5 M NaHPO4 and 2 M NH3OH to the peptide-
mixture followed by 2 M CaCl2. The sample is vortexed
and centrifuged, and, subsequently, the supernatant is
removed before washing the pellet with 80 mM CaCl2.
The washed pellet is dissolved in 5% of formic acid and
the resulting peptide mixture is desalted through reversed
phase chromatography before isolating the phosphopep-
tides by IMAC (Fe
3+).
Zhang and co workers [77] point out that even with
very complex biological samples such as the total enzy-
matic digest of rice embryo proteins, high enrichment of
the phosphopeptides can be achieved with minimal con-
tamination with non-phosphopeptides. In addition, it
could be possible to reduce the complexity of the samples
by successive IMAC enrichments using a limited amount
of IMAC material at each step. This technique demon-
strates that serial phosphopeptide enrichment initiated
by a precipitation step improves the selectivity of phos-
phopeptide enrichment and allows identification of more
phosphopeptides. In addition, Zhang and co workers say
that further analyses to examine the rice phosphopro-
teome in detail are now underway. Moreover, it can be
applied for clinical phosphoproteomics clinical research.
￿ Strong cation and anion exchange (SCX and SAX) The
principle of SCX/SAX phosphopeptide enrichment is
based on the negative charged phosphate group (PO
4-)o f
the phosphopeptides. In cation exchange chromatogra-
phy, a positively charged analyte is attracted to a nega-
tively charged solid-support; whilst in anion exchange
chromatography negatively charged molecules are
attracted to a positively charged solid-support. SAX has
previously been successfully combined with IMAC [66]
and has resulted in greater recovery and identification by
MS of mono-phosphorylated peptides originating from
membrane proteins. In a similar way, SCX has been com-
bined with IMAC (Fe
3+) and MS analysis, allowing the
identification of thousands of phosphorylated residues
from complex biological samples [78]. Moreover, Gruhler
and co-workers [78] demonstrated that use of the SCX/
IMAC combination is consistent with their previous
study where strong anion exchange chromatography/
IMAC was used. Thus, either strong anion exchange
chromatography (SAX) or SCX can be used to reduce
the sample complexity prior to IMAC enrichment of
phosphopeptides in large scale phosphoproteomics.
As practical issues, Nuhse et al., 2003 [66], investigated
and presented a scheme for two-dimensional peptide
separation using SAX chromatography prior to IMAC
(Fe
3+) in order to decrease the complexity of IMAC-puri-
fied phosphopeptides, obtaining a wide coverage of
monophosphorylated peptides. Nuhse and co-workers
did, in fact, obtain a high yield in identifying phospho-
peptides from membrane proteins. SCX has also been
successfully used coupled to IMAC (Fe
3+) and MS analy-
sis allowing the identification of thousands of phosphory-
lated residues from biological complex samples [78,79].
Gruhler and co-workers showed that performing SCX at
low pH (2.7-3.0), phosphorylated peptides are separated
from nonphosphorylated species according to the charge
difference associated with the negatively charged phos-
phate group. Therefore, net charged peptides (+1) were
collected in the first fractions of the SCX prefraction step
containing mainly single phosphorylated peptides. These
first fractions were then loaded onto IMAC (Fe
3+)m i c r o
tips in order to recover a large number of phosphopep-
tides from biologically complex samples.
￿ Hydrophilic interaction chromatography (HILIC)
Hydrophilic interaction chromatography (HILIC) is a
less commonly used method for peptide fractionation
despite the fact that it is often used to fractionate small
metabolites. HILIC is commonly described as partition
chromatography or liquid/liquid extraction system
between the mobile and stationary phase. A water-poor
layer of mobile phase versus a water-rich layer on the
surface of the polar stationary phase is formed. Thus, a
distribution of the analytes between these two layers will
occur. In addition, HILIC includes weak electrostatic
mechanisms as well as hydrogen donor interactions
between neutral polar molecules under high organic elu-
tion conditions. This distinguishes HILIC from ion
exchange chromatography - the main principle for
HILIC separation is based on the compound’sp o l a r i t y
and degree of salvation. More polar compounds will
have stronger interaction with the stationary aqueous
layer than less polar compounds - resulting in a stronger
retention. In addition, HILIC shows a very good separa-
tion and peak shape for critical compounds like adeno-
sine and its phosphate derivatives.
It is of interest to note that Alburquerque and co-work-
ers (2008) [80] carried out a study related to the separa-
tion of unphosphorylated peptides using SCX, HILIC,
and RP-HPLC, indicating that a better orthogonal separa-
tion could occur between HILIC and RP-HPLC for
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separation between HILIC and RP-HPLC is probably a
reflection of their different mechanisms of separation.
Although RP-HPLC depends on interaction with the
hydrophobic amino acid side chains, HILIC depends on
interaction with those hydrophilic and possibly charged
amino acid residues via hydrogen bonding and ionic
interactions. Moreover, because phosphopeptides are
generally hydrophilic and charged, one would expect that
phosphopeptides should interact more strongly with
HILIC than do unphosphorylated peptides. Thus, it
should be possible to separate phosphopeptides using
HILIC.
Dean E. McNulty and Roland S. Annan (2008) [81]
reported the use of hydrophilic interaction chromatogra-
phy (HILIC) as part of a multidimensional chromatogra-
phy strategy for proteomics. Analysis of tryptic digests
from HeLa cells yielded numbers of protein identifications
comparable to those obtained using strong cation
exchange. They also demonstrate that HILIC represents a
significant advance in phosphoproteomics analysis. In fact,
they exploited the strong hydrophilicity of the phosphate
group to selectively enrich and fractionate phosphopep-
tides based on their increased retention under HILIC con-
ditions. In addition, in this study IMAC enrichment of
phosphopeptides from HILIC fractions showed more than
99% selectivity. This was achieved without the use of deri-
vatization or chemical modifiers. In a 300 μg equivalent of
HeLa cell lysate over 1000 unique phosphorylation sites
were identified. More than 700 novel sites were added to
the HeLa phosphoproteome.
￿ Reverse phase chromatography All the phosphorylated
proteins and phosphopeptides isolations can be coupled
to reverse phase chromatography. Subsequently, most
phosphoprotein-phosphopeptide analyses are performed
nowadays by MS. As the MS technique is sensitive to
contaminants such as salts, it is necessary to clean the
samples prior to analysis, generally by reversed phase
chromatography combining POROs R3 with C18 Disks
and also graphite powder [82-84]. Poros R3, C18 Disks
and graphite powder are materials containing long hydro-
carbon chains, proven to be effective for the desalting
and cleaning of very hydrophilic peptides, including phos-
phopeptides [71,85]. In 1999, Gobom and co-workers
[82] introduced a micro column purification method in
which a chromatographic resin was packed in the tip of a
small constricted GELoader tip, creating a micro-column.
With GELoader tips packed with R3, C18 or graphite
material, contaminants like salts can be separated from
the phosphopeptides using a chromatographic approach.
In fact, using RP chromatography, molecules such as pro-
teins, peptides and nucleic acids are separated according
to their hydrophobicity. In addition to the removal of
salts, these techniques also facilitate a concentration of
the sample by the use of a low elution volume. This is an
additional improvement for the sensitivity and quality of
the subsequent mass spectrometric analysis. RP chroma-
tography is usually coupled to all the phosphoproteins
and phosphopeptides enrichment-methods previously
described.
￿ Current methodologies for the detection of phosphory-
lated proteins - Advantages and limitations There are
several analytical techniques for the analysis of phosphor-
ylation, i.e., Edman sequencing and
32P-phosphopeptide
mapping for localization of phosphorylation sites; how-
ever, these methods do not allow high-throughput analy-
sis or imply very high- labour operations [86], whereas
with the use of Mass Spectrometry (MS) high-throughput
analysis of phosphorylated protein residues can be devel-
oped [67,78]. On the other hand, phosphospecific antibo-
dies are routinely used to immunoprecipitate and
therefore enrich in phosphorylated proteins from com-
plex mixtures [87], but, currently, no commercial antibo-
dies are available which are suitable for enriching all
proteins that are phosphorylated, and thus, these proteins
must be purified or enriched from complex mixtures
using alternative methods [88]. By carrying out in-gel or
in-solution trypsin digestion of protein complex mixtures,
the resulted phosphopeptides and non-phosphopeptides
can be loaded into different metal ion chromatographies
(i.e. Immobilized Metal ion Affinity Chromatography
IMAC (Fe
3+), and Titanium Dioxide TiO2 [71] in order
to enrich in phosphopeptides. The enriched solution can
also be submitted into different reverse-phase chromato-
graphies (i.e. Graphite powder [89], POROS R3 [88] in
order to clean and desalt those phosphopeptides pre-
viously eluted. In addition these kinds of chromatogra-
phies will reduce the suppression of phosphorylated
peptides in the mass spectra.
Using IMAC (Fe
3+) and also (TiO2) [71] and (ZrO2) [1],
the negatively charged phosphopeptides are purified by
their affinity to positively charged metal ions, but some of
these methods experience the problem of binding acidic,
non-phosphorylated peptides. Ficarro and co-workers [67]
bypased this problem on IMAC (Fe
3+) by converting acidic
peptides to methyl esters but increased the spectra com-
plexity and requiring lyophilization of the sample, which
causes adsorptive losses of phosphopeptides in particular
[90]. Ficarro et al., were able to sequence hundreds of
phosphopeptides from yeast, including Slt2p kinase, but
the level of phosphorylated residues identified from
kinases were low compared to those from phosphopro-
teins highly expressed within the cell. Recently, TiO2 chro-
matography using 2,5-dihydroxybenzoic acid (DHB) was
introduced as a promising strategy by Larsen et al., [71].
TiO2/DHB resulted in a higher specificity and yield as
compared to IMAC (Fe
3+) for the selective enrichment of
phosphorylated peptides from model proteins (i.e.
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has been developed in order to get a higher efficiency than
IMAC and TiO2 for the isolation of as many phosphopep-
tides as possible [74].
The fact that mainly phosphopeptides from highly
expressed proteins within cells can be purified, while
those from phosphorylated proteins with low level
expression (i. e. kinases) do not bind so well to those
resins, constitutes another important limitation concern-
ing phosphoenrichment methods This is due to the low
proportion of this kind of protein, or, on the other
hand, their available amount binds to metal ions
although it is not sufficient to be detected by MS. The
combination of SCX with IMAC (Fe
3+) has been proven
on yeast, resulting in a huge number of phosphorylated
residues identified (over 700 including Fus3p kinase)
[78]. Although more than 100 signalling proteins and
functional phosphorylation sites, including receptors,
kinases and transcription factors, were identified, it was
clear that only a fraction of the phosphoproteome was
revealed [78]. In addition, recent combinations of HILIC
with IMAC (Fe
3+)h a v eb e e np r o v e ni nc l i n i c a ls t u d i e s
(HeLa samples), with the result of the identification of a
large number of phosphorylated residues (1000) [81].
Improvement in methodologies to enrich for phos-
phorylated residues from kinases is clearly necessary.
However, this is not straightforward for several reasons:
(a) The low abundance of those signalling molecules
within cells, (b) The stress/stimulation time-duration, as
only a small fraction of phosphorylated kinases are avail-
able at any given time as a result of a stimulus. The
time adaptation over signalling pathways is also a rele-
vant and fast factor for kinases phosphorylation [91].
￿ Summary - phosphoprotein and phosphopeptide
enrichments based on electrostatic interactions The
most common techniques for enrichment for individual
and/or global phosphorylation are IMAC and Titanium
Dioxide (TiO2) [45], which are based on the high affinity
of positively charged metal ions. However, conversion of
carboxylate groups to esters effectively eliminates non-
specific retention of non-phosphorylated peptides,
although this constitutes a drawback due to increased
complexity in the subsequent MS analysis.
D u r i n gt h el a s tf i v ey e a r s ,t i t a n i u md i o x i d e( T i O 2)h a s
emerged as the most common of the metal oxide affinity
chromatography (MOAC) based phosphopeptide enrich-
ment methods. This technique offers increased capacity
compared to IMAC resins in order to bind and elute
mono-phosphorylated peptides. TiO2 exploits the same
principle as IMAC, and is similarly prone to nonspecific
retention of acidic nonphosphorylated peptides. However,
when loading peptides in 2, 5-dihydroxybenzoic acid
(DHB) [71], glycolic and phthalic acids, nonspecific bind-
ing to TiO2 is reduced, thereby improving phosphopeptide
enrichment without a chemical modification of the sam-
ple. In addition, TiO2 is often considered to be inter-
changeable with IMAC. It works on similar levels of
sample amounts (e.g., micrograms of protein) for the iden-
tification of phospho-sites by MS analysis. Recently,
SIMAC [72,74] appeared as a phosphopeptide enrichment
tool which exploits the properties of IMAC coupled to
TiO2, making it possible to carry out more refined studies.
Another phosphopeptide enrichment prior to mass spec-
trometric analysis is ZrO2 [75] and its principle is based
on metal affinity chromatography like IMAC and TiO2.
ZrO2 permits the isolation of single phosphorylated pep-
tides in a more selective manner than TiO2. It has, in fact,
been successfully used in the large-scale characterization
of phosphoproteins [66,78-80]. Furthermore, strategies
which consist of fractionating and subsequently enriching
phosphopeptides on a proteome wide scale are based on
strong cation/anion exchange (SCX and SAX) chromato-
graphy and HILIC interaction chromatography. Calcium
phosphate precipitation is also a useful pre-fractionation
step to simplify and enrich phosphopeptides from complex
samples which can be coupled to IMAC [77].
B.3. Phosphopeptides isolated by Proteomic techniques
-M Sa n a l y s i sPhosphorylation on serine and threonine
residues are labile and conventional fragmentation CID
(Collision Induced Dissociation) typically results in the
partial neutral loss of phosphoric acid (H3PO4, 98/z) in
MS2 mode, due to the gas phase b-elimination of the
phosphor-ester bond. Therefore, dehydroalanine and
dehydroaminobutyric acid are generated. When peptide
ions are fragmented by CID, series of y- and b- ions are
formed [92,93]. By correlating mass difference between
peaks in the y-ion series or between peaks in the b- ion
series with amino acid residue masses the peptide
sequence is obtained. The CID fragmentation occurs on
the peptide backbone, and only limited sequence infor-
mation is obtained. This event can also compromise the
identification of phosphorylation sites. In relation to
phosphotyrosine residues, partial neutral loss is also
observed (HPO3, 80/z) in MS2 mode, but the phosphate
group on tyrosine residues is more stable than on serine
and threonine residues. In addition, the phospho-finger-
print characteristic of phosphotyrosine, is the phospho-
tyrosine immonium ion (~216 Da), this being a positive
indicator for the presence of a peptide phosphorylated
on tyrosine [94,95]. The ion originating from neutral
loss of phosphoric acid (H3PO4) can be selected for
further fragmentation by MS3 mode. After neutral loss
fragmentation, the selected ion is automatically selected
for further fragmentation. This makes it possible to add
extra energy for the fragmentation of peptide backbone.
However, the MS3 mode requires that the phosphoryla-
tion on serine and threonine residues are labile and con-
ventional fragmentation CID (Collision Induced
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of phosphoric acid (H3PO4, 98/z) in MS2 mode, due to
the gas phase b-elimination of the phosphor-ester bond.
Therefore, dehydroalanine and dehydroaminobutyric
acid are generated. When peptide ions are fragmented
by CID, series of y- and b- ions are formed [92,93]. The
peptide sequence is obtained by correlating mass differ-
ence between peaks in the y-ion series or between peaks
in the b-ion series with amino acid residue masses. The
CID fragmentation occurs on the peptide backbone, and
only limited sequence information is obtained. This
event can also compromise the identification of phos-
phorylation sites. In relation to phosphotyrosine resi-
dues, partial neutral loss is also observed (HPO3, 80/z)
in MS2 mode, but the phosphate group on tyrosine resi-
dues is more stable than on serine and threonine resi-
dues. In addition, the phospho-finger-print characteristic
of phosphotyrosine, is the phosphotyrosine immonium
ion (~216 Da), which is a positive indicator for the pre-
sence of a peptide phosphorylated on tyrosine [94,95].
The ion originating from neutral loss of phosphoric acid
(H3PO4) can be selected for further fragmentation by
MS3 mode. The selected ion, after neutral loss fragmen-
tation, is automatically selected for further fragmenta-
tion. This makes it possible to add extra energy for the
fragmentation of peptide backbone. However, the MS3
mode requires that the selected ion is abundant in order
to observe the fragmented ions. A pseudo-MS3 develop-
ment is MultiStage Activation (MSA) [96], which was
implemented on quadrupole-IT and linear IT-orbitrap.
In MSA, the fragmentation of the precursor ion occurs
simultaneously with the fragmentation of the ion origi-
nating from the neutral loss. The MS2 and MS3 mass-
data are then combined in a hybrid spectrum, resulting
in improved sequence information and also in an
improvement of reliance for the phosphorylation site
assignment. Alternative fragmentations to CID are ECD
(electron capture Dissociation) and ETD (Electron trans-
fer dissociation). By ECD, radical peptide ions are
obtained when multiplycharged peptide ions are
rationed with low-energy thermalelectrons. In addition,
this fragmentation occurs in the peptide between the
backbone amide and the alpha carbon, generating c-
and z-ions [97]. An advantage of ECD is that it only
occurs on the peptide backbone, and labile phosphate
groups remain intact on the resulting c- and z- fragment
ions, thus enabling the identification of the specific
phosphorylation sites. Therefore, it is extremely useful
for the analysis of multiply-phosphorylated peptides. A
disadvantage of ECD is its selectivity for disulfide bonds,
due to the high radical affinity of the bond [98,99]. The
main drawback of ECD is that it is solely used in the
Fourier transform-Ion Cyclotron Resonance (FT-ICR)
instruments due to the requirement of a static magnetic
field for the thermal electrons, meaning high costs and
high specialization. c- and z- ions are also generated by
ETD. This fragmentation was actually developed in
order to carry out ECD-like dissociation experiments, in
a Quadrupole Linear Ion Trap [96,100]. ETD is a chemi-
cal process in which reaction with fluoranthene radical
anions disrupts the peptide backbone at regular inter-
vals. ETD preserves the intact information about labile
modifications, which are not observed directly when
using CID. For instance, phosphate groups are good
leaving groups, which mean that they are easily lost in
the excitation process. However, by using ETD one can
directly observe fragments that contain the intact phos-
phopeptides. The drawback of ETD is that it is less sen-
sitive compared to CID, because of lower ionization
efficiency. As a result, we recommend using CID to
start with, and would recommend switching to ETD in
case you are not able to determine the phosphorylation
site.
(C) Quantitative proteomic methodologies used in clinical
research; examples of relevant phosphorylated proteins
studied
For phosphopeptides proteins containing amino acids with
one or more of the stable isotopes of
2H,
13C,
15No r
18O
can be used as internal standards by addition, at an early
stage of the analysis, of a complex protein sample. There
are two approaches for introducing a stable isotope into
proteins or peptides: metabolic labelling using whole cells
grown in culture (e.g. SILAC) or chemical labelling (e.g.
iTRAQ, ICAT). Since protein phosphorylation is very
dynamic and constantly changing throughout the life of a
cell, measuring the changes in phosphorylation is critical
for understanding the biology of a phosphorylation event,
We restrict the discussion here to four MS based quantita-
tion strategies which have direct utility towards measuring
changes in protein phosphorylation extensively: SILAC,
iTRAQ, AQUA and MRM. Other chemical labelling tech-
niques which rely on stable isotope incorporation using
e.g.
18O labelled water during trypsin digestions and stable
isotope incorporation ICAT can also be considered to
contain relevant information, but will not be described
here. In addition, we will also include the explanation and
examples of 2-D Fluorescence Difference Gel Electrophor-
esis (2D_DIGE) quantification methodology, which nowa-
days also provides interesting research studies.
C.1. Stable Isotope Labelling with Amino acid in cell
Culture (SILAC) Stable isotope labelling by amino acids
in cell culture (SILAC) is a quantitative method based on
in vivo labelling of proteins in cell cultures with amino
acids that contain stable isotopes (non radioactive, e.g.
2H,
13Ca n d
15N) [57,101]. In its simplest form, two sepa-
rated cell cultures are grown in a pair-wise fashion; for
example, culture A might be yeast cells grown under
“normal” conditions (light conditions) while culture B
López et al. Proteome Science 2011, 9:27
http://www.proteomesci.com/content/9/1/27
Page 11 of 20might be yeast cells grown in the presence of a stress
condition. The growth conditions of the cells are identical
(except for the presence of the stress stimuli), but the
growth media of culture B has an essential amino acid
(one not synthesized by the cell) replaced with an isotopi-
cally “heavy” form of that amino acid (e.g.
13C6-arginine).
A number of cell lines have been used for SILAC experi-
ments, and the growth and morphology of the cells have
not been affected by the isotopically labelled amino acid
[78,101,102].
After approximately five rounds of doubling, cellular
proteins are essentially 100% labelled with the selected
amino acid. After culturing, the light and heavy cell
populations are combined (1:1) into one pool and the
proteins are isolated. The protein pool is then digested
with a protease, typically trypsin, to form a peptide pool
that is analyzed by MS. Each peptide analyzed will be
present in two forms: the light and the heavy form. They
are distinguishable based on the mass difference due to
the heavy isotope incorporation in the selected amino
acid. The SILAC method is compatible with the above
mentioned enrichment of phosphoproteins/phosphopep-
tides including the immunoprecipitation of a target pro-
tein [103]. One of the first research studies which
carryied out this technology was provided by Gruhler
and co-workers (2005) [78]. In this study, more than 700
phosphopeptides from Sacharomyces cerevisiae were
identified, 139 were differentially regulated at least 2-fold
in response to mating pheromone. Components belong-
ing to the mitogen-activated protein kinase signalling
pathway and to downstream processes including tran-
scriptional regulation, the establishment of polarized
growth, and the regulation of the cell cycle were among
these regulated proteins.
C.2. Isobaric Tag for Relative and Absolute (iTRAQ)
The second method for the global quantification of pro-
teins and protein modifications is an in vitro chemical
labelling procedure called iTRAQ. The iTRAQ reagent
consists of two to eight isobaric tags that can be used to
label two to eight separate protein samples. The iTRAQ
tags contain three regions: a peptide reactive region, a
reporter region, and a balance region [104]. The peptide
reactive region of the tag consists of an NHS ester and is
designed to react with the N-termini and lysines of pep-
tides after protease digestions. In the case of 4-plex
iTRAQ, the four reporter groups appear in the tandem
mass spectrum at m/z 114, 115, 116, and 117. The
attached balance groups are designed to make the total
mass of the balance and reporter group 145 Da for each
tag, which results in balance groups of 31 Da, 30 Da, 29
Da, and 28 Da, respectively. Protein samples for quantifi-
cation are separately isolated and digested proteolytically,
and each sample is chemically labelled with one of
the iTRAQ reagents. After labelling, the samples are
combined and subsequently analyzed by MS. Identical
peptides from each sample will have identical masses as
the iTRAQ reagents are isobaric The iTRAQ reagent
labels phosphopeptides to the same degree as nonpho-
sphorylated peptides and it does not affect the stability of
phosphopeptides. Enrichment strategies, such as IMAC
[44,105] or immunoprecipitation with anti-phosphotyro-
sine antibodies [44], have been used to remove non-phos-
phorylated peptides to focus the analysis on site-specific
phosphorylation. Since iTRAQ is an in vitro labelling
procedure it can also be applied to clinical samples such
as tumour tissues and fluids (e.g. serum, urine, blood).
iTRAQ has been described as a very powerful method for
the quantification of phosphorylation on a proteomic
scale. As a relevant example we mention that Boja and
co-workers (2009) [106] successfully monitored phos-
phorylation sites of mitochondrial proteins including ade-
nine nucleotide translocase, malate dehydrogenase and
mitochondrial creatine kinase, etc. Among them, four
proteins exhibited phosphorylation changes with these
physiological stimuli: (a) BCKDH-E1a subunit increased
phosphorylation at Ser337 with DCA and de-energization;
(b) apoptosis-inducing factor phosphorylation was ele-
vated at Ser345 with calcium; (c) ATP synthase F1 com-
plex a subunit and (d) mitofilin dephosphorylated at
Ser65 and Ser264 upon de-energization. This screening
validated the iTRAQ/HCD technology as a method for
functional quantitation of mitochondrial protein phos-
phorylation as well as providing insights into the regula-
tion of mitochondria via phosphorylation.
C.3. Absolute Quantitation (AQUA) The AQUA strategy
provides an absolute quantification of a protein of inter-
est [107]. In the AQUA method, a peptide from the pro-
tein of interest is constructed synthetically containing
stable isotopes, and the isotopically labelled synthetic
peptide is called AQUA peptide. The synthetic peptides
can be synthesized with modifications such as phosphory-
lation to allow for the direct, quantitative analysis of post-
translationally modified proteins. The stable isotopes are
incorporated into the AQUA peptide by using isotopically
“heavy” amino acids during the synthesis process of the
interesting peptide (native peptide). In this way, the syn-
thetic peptide has a mass increase of e.g. 10 Daltons, due
to the incorporation of a 13C6 and 15N4-arginine into
the synthetic peptide, compared to the native peptide.
Although the mass difference between the native and the
synthetic peptide allows the mass spectrometer to differ-
entiate between the two forms, both forms have the same
chemical properties, resulting in the same chromato-
graphic retention, ionization efficiency, and fragmentation
distribution. In AQUA experiments, a known amount of
the isotopically labelled peptide is added to a protein
mixture, which is proteolytically digested, and later ana-
lyzed by MS. Since the native peptide and its synthetic
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signal from the quantified synthetic peptide can be com-
pared to the signal of the native peptide. The absolute
quantification of the peptide to be determined [108] is
thus finally permitted. Multiple AQUA peptides can be
used to quantify multiple proteins in a single experiment.
Ziwei Yu and co-workers (2007) [109] using AQUA as a
novel system of in situ quantitative protein expression ana-
lysis, studied the protein expression levels of phosphory-
lated Akt (p-Akt). Activation of Akt in tumours is
mediated via several mechanisms, including activation of
cell membrane receptor tyrosine kinases such as EGFR and
loss of phosphatase PTEN with dephosphorylation of phos-
phoinositol triphosphate. Ziwei and co-workers (2007) dis-
covered that Akt activation in oropharyngeal squamous
cell carcinoma (OSCC) is associated with adverse patient
outcome, indicating that Akt is a promising molecular tar-
get in oropharyngeal squamous cell carcinoma.
C.4. Multiple Reaction Monitoring (MRM) MRM is a
very sensitive method for detecting phosphorylated pep-
tides on a hybrid triple quadrupole linear ion trap mass
spectrometer (qTRAP). This method requires that the
sequence of the protein be known in order to calculate
precursor and fragment ion values, which can be used to
trigger dependent ion scans in a qTRAP instrument
[110,111]. This technique can also be used to perform a
precursor ion and neutral loss scan, to identify unknown
phosphopeptides from a complex mixture, and is a
powerful method for the identification and quantification
of post-translational modifications in proteins. MRM has
recently been used by White and co-workers [112,113] to
identify and quantify tyrosine phosphorylated kinases for
hundreds of nodes within a signalling network and across
multiple experimental conditions. Moreover, White and
co-workers [112,113] applied iTRAQ combined with
MRM for phospho quantitative analysis of signalling net-
works, identifying and quantifying 222 tyrosine phos-
phorylated peptides, obtaining an extremely high
percentage of signalling nodes covered. They defined the
mechanisms by which EGFRvIII protein alters cell phy-
siology, as it is one of the most commonly mutated pro-
teins in GBM and has been linked to radiation and
chemotherapeutic resistance. They performed a phospho-
proteomic analysis of EGFRvIII signalling networks in
GBM cells. The results of this study provided important
insights into the biology of this mutated receptor, includ-
ing oncogene dose effects and differential utilization of
signalling pathways. In addition, clustering of the phos-
phoproteomic data set revealed a previously undescribed
crosstalk between EGFRvIII and the c-Met receptor.
Treatment of the cells with a combination using both
EGFR and c-Met kinase inhibitors dramatically decreased
cell viability in vitro.
C.5. 2-D Fluorescence Difference Gel Electrophoresis
(DIGE) In DiGE, proteins extracted from a control extract
are labelled with one CyDye (Cy3 or Cy5 conjugated), and
proteins isolated from a test extract labelled with the
other colour of CyDye fluorophore, which are size and
charge matched. These labelled protein extracts are mixed
and co-resolved (often with the addition of an internal
standard, which can be labelled with Cy2) on large-format
two-dimensional gels for analysis of expression changes in
the resulting pattern of spots (’spot maps’) [114]. In com-
parison with two-dimensional gel electrophoresis, DiGE
offers the advantage that multiple samples could be com-
pared on a single gel (’multiplexing’), and made it possible
to stain control and test samples with different fluorescent
dyes prior to electrophoresis. This advance alleviated
issues of gel-to-gel comparison and decreased the number
of gels required. The capability to include an internal
standard, composed of an equal fraction of all the samples
in an experiment, also improved intergel matching and
facilitated normalization of matched spots in replicate
samples on multiple gels. The use of CyDyes to label pro-
teins, in place of non-fluorescent post-stains, can give a
large enhancement of sensitivity for protein detection
[115] and constitutes the crucial advantage of the DiGE
approach for biomaterial applications. This enables analy-
sis of even very scarce protein samples, including
small areas of laser-microdissected tissue [116,117]. Two-
dimensional difference gel electrophoresis (2D-DIGE) with
novel ultra high sensitive fluorescent dyes (CyDye DIGE
Fluor saturation dye) enables the efficient protein expres-
sion profiling of laser-microdissected tissue samples. The
combined use of laser microdissection allows accurate
proteomic profiling of specific cells including tumour
tissues [118].
As an example, differential protein analysis was per-
formed using 2-dimensional differential in-gel electro-
phoresis (2D-DIGE) by Yefei Rong and co-workers (2010)
[119]. They found that 16 protein spots were differently
expressed between the two mixtures (a comparison was
made with serum samples from five individuals with pan-
creatic cancer and five individuals without cancer). Yefei
Rong and co-workers [119] demonstrated that eight pro-
teins from these fluids were up-regulated and 8 were
down-regulated in cancer. Mass spectrometry and data-
base searching allowed the identification of the proteins
corresponding to the gel spots. Up-regulation of mannose-
binding lectin 2 and myosin light chain kinase 2, which
had not previously been implicated in pancreatic cancer,
were observed. In an independent series of serum samples
from 16 patients with pancreatic cancer and 16 non-can-
cerbearing controls, increased levels of mannose-binding
lectin 2 and myosin light chain kinase 2 were confirmed
by western blot.
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the technology named “antibody proteomics technology”.
This technology can screen for biomarker proteins by iso-
lating antibodies against each candidate in a rapid and
comprehensive manner. He applied “antibody proteomics
technology” to breast cancer-related biomarker discovery
and evaluated the utility of this novel technology. Cell
extracts derived from breast tumour cells (SKBR3) and
normal cells were analyzed by two-dimensional differential
gel electrophoresis (2D-DIGE) in order to identify proteins
over-expressed in the tumour cells. Candidate proteins
were extracted from the gel pieces, immobilized onto a
nitrocellulose membrane using a dot blot apparatus and
then used as target antigens in scFv-phage enrichment
and selection. scFvs binding to 21 different over-expressed
proteins in tumor cells were successfully isolated within
several weeks following this in vitro phage selection proce-
dure. The expression profiles of the identified proteins
were then determined by tissue microarray analysis using
the scFv-phages. Consequently, three breast tumour-speci-
fic proteins were identified. His data demonstrated the uti-
lity of an antibody proteomics system for discovering and
validating tumour-related proteins in pharmaceutical pro-
teomics. Currently, he and other related groups are analyz-
ing the functions of these proteins in order to be able to
confirm and use them as diagnostic markers or therapeu-
tic targets.
(D) Phosphorylated proteins related to different diseases
and the benefits of proteomic strategies in such clinical
studies
In a recent study Steen et al. examined the role of phos-
phorylation in the dynamics of the anaphase promoting
complex (APC) [121]. Some drugs that bind to microtu-
bules and block mitosis are ineffective in cancer treatment;
others show inexplicable focal efficacy. For example, the
vinca alkaloids are useful for treating lymphoma, neuro-
blastoma and nephroblastomas, whereas taxol is useful for
advanced breast cancer and ovarian cancer. It is not
known why these drugs are not all equally effective, nor
why they have different therapeutic value against different
cancers. The authors observed distinct phosphorylation
states of the APC in response to different antimitotic
drugs and suggest they may explain some of these differ-
ences. They also propose it is possible that cells from dif-
ferent tissues, or cells harbouring different mutations, or
cells under different physiological stresses, such as
hypoxia, may differ in their response to spindle poisons
and would thus reflect those differences in different sites
of phosphorylation. Differences in spindle checkpoint
phosphorylation may reveal new features of the mitotic
state. The categorisation of drugs, the discrimination of
the response of tumours to drugs and the identification of
new means of checkpoint control may be facilitated by the
ability to characterise drug candidates based on the
spectrum of APC phosphorylations The authors further
suggest that the results of the study indicate that the term
mitotic arrest is a misnomer: arrest is a dynamic state in
which some cells enter apoptosis and other cells revert to
interphase. The ability to observe biochemical events dur-
ing arrest could be very important for understanding anti-
proliferative treatments. The exploration of the dynamics
of phosphorylation, however, makes great demands on the
accuracy of quantitation. Most mass spectrometric based
quantitative approaches, including stable isotope labelling
with amino acids in cell culture (SILAC) and isobaric tag
for relative and absolute quantitation (iTRAQ), give rela-
tive data, meaning that one state of phosphorylation is
determined relative to another phosphorylation state
[122-124]; these data can help to establish the kinetics of a
pathway. The method used in this work offers a significant
advance over earlier techniques. It allowed the measure-
ment of specific quantitative changes in APC phosphoryla-
tion in cells arrested in nocodazole for varying periods. If
these dynamics can be correlated with the process by
which the arrested state is resolved, we may be provided
with new tools to understand the mitotic process and to
find more effective drug targets in cancer.
The long-held belief in the cancer research community
that a precise molecular understanding of cancer can
result in cancer therapy is validated by the development
of drugs for specific biological pathways with increased
specificity and reduced toxicity. The development of Her-
ceptin, a monoclonal antibody against the HER2 receptor
for breast cancer therapy is one of the most successful
recent examples of cancer-specific drugs. HER2 is an
important target in cancer because its overexpression
increases tumour cell proliferation, vessel formation and
invasiveness, and predicts poor prognosis. Wolf-Yadlin
and other scientists [111,112], [121-124] have used phos-
phoproteomics and MS to investigate the role of phos-
phorylation in the effects of HER2 overexpression on
EGF- and HRG-mediated signalling of erbB receptors.
Identification was possible of specific combinations of
phosphorylation sites that correlate with cell proliferation
and migration and that potentially represent targets for
therapeutic intervention. Unfortunately, owing to sensi-
tivity limitations, only 68 out of 322 phosphorylation
sites could be analysed kinetically, so the study does not
provide a comprehensive analysis of the multitude of
effects produced by HER2 overexpression. It does, how-
ever, mark an important breakthrough in the characteri-
sation of the erbB receptor signalling network in tumours
and illustrates the importance of understanding protein
phosphorylation.
A central role is played by mitochondria in energy
metabolism and cellular survival, and consequently mito-
chondrial dysfunction is associated with a number of
human pathologies. Moreover, mitochondrial dysfunction
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type 2 diabetes. Recently, Zhao and co-workers (2011)
[125], studied the phosphoproteome of the mitochondria
isolated from human skeletal muscle. Zhao and co-
workers revealed extensive phosphorylation of inner
membrane protein complexes and enzymes combining
titanium dioxide (TiO2) protocols with reverse phase
chromatography coupled to MS analysis. 155 distinct
phosphorylation sites in 77 mitochondrial phosphopro-
teins, including 116 phosphoserine, 23 phosphothreo-
nine, and 16 phosphotyrosine residues were identified.
Phosphorylation sites in mitochondrial proteins involved
in amino acid degradation, importers and transporters,
calcium homeostasis, and apoptosis were also assigned.
Furthermore, many of these mitochondrial phosphopro-
teins are substrates for protein kinase A, protein kinase
C, casein kinase II and DNA-dependent protein kinase.
The high number of phosphotyrosine residues suggests
that tyrosine phosphorylation has an important role in
mitochondrial signalling. Many of the mitochondrial
phosphoproteins are involved oxidative phosphorylation,
tricarboxylic acid cycle, and lipid metabolism, i.e. pro-
cesses proposed to be involved in insulin resistance. It is
well known that mitochondria dysfunction is centrally
involved in a number of human pathologies, such as type
2 diabetes, parkinson’s disease and cancer [126]. In this
study, the most prevalent form of cellular protein post-
translational modifications (PTMs), reversible phosphor-
ylation [127-134][135-139], emerges as a central mechan-
ism in the regulation of mitochondrial functions
[130,131]. The steadily increasing numbers of reported
mitochondrial kinases, phosphatases and phosphopro-
teins also imply the important role of protein phosphory-
lation in different mitochondrial processes [132-134].
The prototypical proteomics pipe-line useful for clinical
research is illustrated (Figure 3).
Figure 3 A prototypical proteomics pipe-line useful for clinical research. Depending on the application, different samples processed and
fed into the proteomics pipeline yield different results. The pipeline’s several steps are listed in the different panels: (1) proteolytic digest, (2) the
separation and ionization of peptides, (3) their analysis by MS, (4) fragmentation of selected peptides and analysis of the resulting MS/MS spectra
and, (5) (6) data-computer analysis, which includes identification and quantification of proteins from several detected peptides.
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Cancer and immune disorders are still among the leading
causes of death worldwide. Therefore, there is still a need
for the identification of useful biomarkers and the
improvement of the understanding of the development of
these diseases. The immune system is readily affected by
the existence of cancer in the body, even at a preclinical
stage, and these studies should be expanded and extended
in the future to answer the numerous questions concern-
ing (a) the roles of immune cells in cancer surveillance (b)
the characteristics of inflammation in association with
cancer development, (c) the effects of environment/life-
style factors on the immune system, and (d) the interac-
tion between aging diseases. The importance of protein
kinase-regulated signal transduction pathways in immu-
nology disorders and cancer has led to the development of
drugs that inhibit protein kinases at the apex or intermedi-
ary levels of these pathways. Protein phosphorylation
assignment studies of these signalling pathways will pro-
vide important insights into the operation and connectivity
of these pathways that will facilitate the identification of
the best targets for cancer therapies and immunology dis-
eases (e.g. the identification of a phosphate group on a
specific serine, threonine or tyrosine by phosphoenrich-
ments combined with MS). Phosphoproteomic analysis of
individual tumours, blood, sera, tissues will also help
match targeted therapeutic drugs to the appropriate
patients. It is now generally accepted that no single pro-
teomic method is comprehensive, but combinations of dif-
ferent enrichment methods produce distinct overlapping
phosphopeptide datasets to enhance the overall results in
phosphoproteome analysis. During the last decade, phos-
phopeptide sequencing by mass spectrometry has seen tre-
mendous advances. For example, MS/MS product ion
scanning, multistage activation and precursor ion scanning
are effective methods for identifying serine (Ser), threonine
(Thr) and tyrosine (Tyr) phosphorylated peptides.
The current phosphoproteomic goals imply the identifi-
cation of phosphoproteins, mapping of phosphorylation
sites, quantitation of phosphorylation under different con-
ditions, and the determination of the stoichiometry of the
phosphorylation. In addition, knowing when a protein is
phosphorylated, which kinase/s is-are involved, and how
each phosphorylation fits into the signalling network, are
also important challenges for researchers in order to
understand the significance of different biological events.
The new MS technologies are fundamental for cataloguing
all this information, and it is heading towards the collec-
tion of accurate data on phosphopeptides on a global
scale. In addition, the possible difficulties to get sufficient
amount of specific phosphorylated proteins of specific low
abundant protein-kinases in vivo which might limit the
usability of the phosphoproteome analysis, must be
pointed out.
Finally, it is important to state that to develop clinical
proteomic applications using the identified proteins and
phosphoproteins, collaboration between research scien-
tists, clinicians and diagnostic companies, and proteomic
experts is essential, particularly in the early phases of the
biomarker development projects. The proteomics modal-
ities currently available have the potential to lead to the
development of clinical applications, and channelling the
wealth of the information produced towards concrete and
specific clinical purposes is urgent.
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Cyclotron Resonance; HILIC: Hydrophilic interaction chromatography; HPLC:
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MSA: MultiStage Activation; MS/MS: tandem mass spectrometry; m/z: Mass
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